Form 4: Xenon Pharmaceuticals Director Gary Patou Granted Stock Options

Director Gary Patou of Xenon Pharmaceuticals Inc. was granted stock options exercisable for 15,542 common shares on June 5, 2024.

Summary

• Gary Patou, a director of Xenon Pharmaceuticals Inc., filed a Form 4 on June 5, 2024.
• The filing reports the grant of stock options to Patou, exercisable for 15,542 common shares.
• The exercise price of the options is $38.16 per share.
• The options vest on the earlier of June 4, 2025, or the day before the issuer's 2025 annual meeting of shareholders, and expire on June 4, 2034.
• Patou also granted a Power of Attorney effective March 8, 2024, authorizing Sherry Aulin, Andrea DiFabio, Ilona Lo, and Nathaniel Adams to act on his behalf in matters related to SEC filings.

Sentiment

Score: 6

Explanation: The document is a routine filing related to executive compensation. It is neutral in tone and does not contain information that would significantly impact investor sentiment.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders.
• The vesting schedule provides an incentive for continued service and performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded pharmaceutical companies.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term value creation.
• Comparable companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates